➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Medtronic
Harvard Business School

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

POTASSIUM CHLORIDE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Potassium Chloride patents expire, and when can generic versions of Potassium Chloride launch?

Potassium Chloride is a drug marketed by Actavis Labs Fl Inc, Adare Pharms Inc, Amneal Pharms, Anchen Pharms, Glenmark Pharms Ltd, Lannett Co Inc, Lupin Ltd, Nesher Pharms, Novel Labs Inc, Paddock Llc, Prinston Inc, Strides Pharma, Teva, Tris Pharma Inc, Zydus Pharms, Amneal Pharms Llc, Belcher, Epic Pharma Llc, Pharma Res Software, Abraxis Pharm, Akorn, B Braun, Baxter Hlthcare, Fresenius Kabi Usa, Gd Searle Llc, Hospira, Intl Medication, Lilly, Luitpold, Miles, Pharma Serve Ny, Watson Labs, Apotex, Genus Lifesciences, Pharm Assoc, Amneal, Aurobindo Pharma Ltd, Copley Pharm, Granules Pharms, Mylan, PII, Schering, Sigmapharm Labs Llc, Vitruvias Therap, Yichang Humanwell, and Icu Medical Inc. and is included in ninety-eight NDAs.

The generic ingredient in POTASSIUM CHLORIDE is calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate. There are two hundred and eighty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate profile page.

US Patents and Regulatory Information for POTASSIUM CHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs POTASSIUM CHLORIDE potassium chloride INJECTABLE;INJECTION 089163-001 Mar 10, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
Icu Medical Inc POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER dextrose; potassium chloride; sodium chloride INJECTABLE;INJECTION 018365-009 Mar 28, 1988 DISCN Yes No   Start Trial   Start Trial   Start Trial
Nesher Pharms POTASSIUM CHLORIDE potassium chloride TABLET, EXTENDED RELEASE;ORAL 076044-001 Apr 5, 2002 DISCN No No   Start Trial   Start Trial   Start Trial
Icu Medical Inc POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER potassium chloride INJECTABLE;INJECTION 020161-002 Nov 30, 1992 AP RX Yes No   Start Trial   Start Trial   Start Trial
Baxter Hlthcare POTASSIUM CHLORIDE potassium chloride INJECTABLE;INJECTION 080203-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for POTASSIUM CHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering POTASSIUM CHLORIDE potassium chloride TABLET, EXTENDED RELEASE;ORAL 019439-002 Jun 13, 1986   Start Trial   Start Trial
Schering POTASSIUM CHLORIDE potassium chloride TABLET, EXTENDED RELEASE;ORAL 019439-001 Jun 13, 1986   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for POTASSIUM CHLORIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1441735 SPC/GB08/020 United Kingdom   Start Trial PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
1718641 SPC/GB12/028 United Kingdom   Start Trial PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
1499331 SPC/GB13/034 United Kingdom   Start Trial PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
1499331 13C0055 France   Start Trial PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
0733366 SPC/GB98/031 United Kingdom   Start Trial PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.